TY - JOUR
T1 - Bronchiolitis obliterans syndrome
T2 - Pathogenesis and management
AU - Hachem, Ramsey R.
AU - Trulock, Elbert P.
PY - 2004/1/1
Y1 - 2004/1/1
N2 - Over the past 15 years, lung transplantation has become an established treatment for a variety of end-stage lung diseases, but medium- and long-term success has been limited by a high incidence of bronchiolitis obliterans syndrome (BOS). Immune mediated injury has been recognized as the leading cause of BOS, and the term is synonymous with chronic rejection. But recently, nonimmune mechanisms, such as gastroesophageal reflux, have been recognized as potential culprits. The results of various treatment options have generally been disappointing, and BOS has emerged as the leading cause of late morbidity and mortality after lung transplantation.
AB - Over the past 15 years, lung transplantation has become an established treatment for a variety of end-stage lung diseases, but medium- and long-term success has been limited by a high incidence of bronchiolitis obliterans syndrome (BOS). Immune mediated injury has been recognized as the leading cause of BOS, and the term is synonymous with chronic rejection. But recently, nonimmune mechanisms, such as gastroesophageal reflux, have been recognized as potential culprits. The results of various treatment options have generally been disappointing, and BOS has emerged as the leading cause of late morbidity and mortality after lung transplantation.
KW - Bronchiolitis obliterans syndrome
KW - Lung transplantation
KW - Rejection
UR - http://www.scopus.com/inward/record.url?scp=11844284855&partnerID=8YFLogxK
U2 - 10.1053/j.semtcvs.2004.09.011
DO - 10.1053/j.semtcvs.2004.09.011
M3 - Review article
C2 - 15635539
AN - SCOPUS:11844284855
SN - 1043-0679
VL - 16
SP - 350
EP - 355
JO - Seminars in Thoracic and Cardiovascular Surgery
JF - Seminars in Thoracic and Cardiovascular Surgery
IS - 4
ER -